

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

**SUPPLEMENTAL NOTICE OF 2023 ANNUAL GENERAL MEETING**

Reference is made to the notice of annual general meeting (the “AGM”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) dated May 21, 2024 (the “Original Notice of AGM”) which sets out the time and venue of the AGM and contains the resolutions to be proposed at the AGM for approval by the shareholders of the Company. This supplemental notice shall be read together with the Original Notice of AGM.

**SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT** the AGM of the Company will be held as originally scheduled at 8:00 a.m. on June 20, 2024 at Meeting Room 1, R&D Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the People’s Republic of China. In addition to the resolutions set out in the Original Notice of AGM, the resolutions set out below shall be proposed at the AGM. The resolutions in the Original Notice of AGM numbered 10, 11, 12(a), 12(b), 13(a) and 13(b) shall be renumbered as 11, 12, 13(a), 13(b), 14(a) and 14(b), respectively.

**ORDINARY RESOLUTION**

10. To consider and approve the proposed appointment of Mr. LAI Degui as a non-executive Director of the third session of the Board.

**SPECIAL RESOLUTION**

14. (c) To consider and approve the proposed amendments to the articles of association of the Company as set out in the supplemental circular of the Company dated May 31, 2024 which result from the resignation of Supervisors.

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, May 31, 2024

*Notes:*

1. A revised form of proxy (the “**Revised Proxy Form**”) containing ordinary resolution number 10, special resolution number 14(c) and the renumbered resolutions of the Original Notice of AGM is published on the websites of the Stock Exchange and the Company. Please refer to the section headed “Proxy Arrangement” on pages 6 to 7 of the supplemental circular of the Company dated May 31, 2024 (the “**Supplemental Circular**”) for arrangements on the completion and submission of the Revised Proxy Form.
2. Please refer to the Original Notice of AGM for details of the other resolutions to be considered at the AGM, closure of the register of members of the Company and eligibility for attending the AGM and other relevant matters.
3. Further details of the above resolutions are set out in the Supplemental Circular. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the Supplemental Circular.
4. References to dates and time in this notice are to Hong Kong dates and time.

*As at the date of this notice, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*